Premature Babies are in more safe hand with BabyLux

First results of the European project BabyLux obtained in Milan and Copenhagen are encouraging

412

For the first time, two advanced biophotonic technologies – near-infrared time-resolved spectroscopy (TRS) and diffuse correlation spectroscopy (DCS) – have been combined and the already tested prototypes were extended to the level of demonstrators. Two devices were installed and used by doctors for six months in the neonatology units at the Rigshospitalet in Copenhagen, Denmark and at the Fondazione IRCCS Ca’ Granda – Ospedale Maggiore Policlinico in Milan, Italy. The project goal is to reduce the risk of brain lesions in extremely preterm babies. The core opto-electronic components necessary for this novel instrument are provided by the German company PicoQuant, a leading provider of instrumentation for single photon counting applications.

The first results obtained in the framework of the European project BabyLux are encouraging. As a part of the protocol, 60 measurements have been performed with 35 babies enrolled during their first days of life at the two centers. The technology developed in this project allows continuous and non-invasive monitoring of brain perfusion and oxygenation, which is still lacking on the market. The device is safe with regards to acute adverse reactions, can be brought to the bedside, and allows for continuous monitoring, both under critical and non-critical conditions, as each measurement takes only a few minutes.

This first trial phase was focused on the evaluation of test/re-test variability as a precision benchmark. The tests revealed that moving the sensor from one site to another on the head resulted in a variability of less than 5% in microvascular blood oxygenation values and in a 15 to 25% variability in microvascular cerebral blood flow indexes. These values are better than or comparable with currently existing commercial devices.

 “We are very contented with the positive results of the trial phase,” says Rainer Erdmann, Managing Director at PicoQuant. “To contribute our knowledge and class leading opto-electronic components to a such a successful project dedicated to baby health makes us proud. We are looking forward for seeing the complete instrument in use in hospitals very soon.”

LEAVE A REPLY